Progression of colorectal cancer (CRC) generally coincides with successive alterations in four signalling pathways: WNT, EGFR, p53 and TGFβ 5,8 . Mice bearing compound mutations in these four pathways were recently shown to enable the study of CRC metastasis 9-11 . We crossed mice bearing conditional alleles in homologues of four key human CRC mutations: Apc fl/fl , Kras 
, T-cell exclusion 3 and TGFβ-activated stroma 4, 6, 7 . Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the T H 1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.
Progression of colorectal cancer (CRC) generally coincides with successive alterations in four signalling pathways: WNT, EGFR, p53 and TGFβ 5, 8 . Mice bearing compound mutations in these four pathways were recently shown to enable the study of CRC metastasis [9] [10] [11] . We crossed mice bearing conditional alleles in homologues of four key human CRC mutations: Apc fl/fl , Kras , Tgfbr2 fl/fl and Trp53 fl/fl (designated A, K, T and P, respectively) [12] [13] [14] [15] , and targeted gene recombination to intestinal stem cells (ISCs) by means of the Lgr5 driver 16 , which we designated L. We generated eight mouse strains bearing combinations of these mutations (Fig. 1a) . Histopathological scoring demonstrated a stepwise increase in prevalence and severity of invasive adenocarcinomas along the linear progression sequence (Fig. 1b, . Ninety per cent of LAKTP mice developed carcinomas, more than half of which breached all intestinal layers (Fig. 1c) . These cancers displayed a histology similar to human tumours, with mostly medium to high degrees of differentiation and abundant desmoplastic reaction (Extended Data Fig. 1d-j) . Forty per cent of LAKTP mice developed metastases in the liver or lungs, or as carcinomatosis , with a median latency of 66 days. Notably, mice bearing triple-mutant genotypes (LAKT, LATP or LAKP) presented with similarly invasive cancers but not metastasis (Fig. 1c) . In LAKTP mice, T cells extensively infiltrated the stroma of normal mucosa and adenomas but were largely excluded from adjacent invasive cancers ( Fig. 1e and Extended Data Fig. 2a ). This exclusion phenotype intensified along the CRC mutational sequence (Fig. 1e ). Invasive margins of compound-mutant cancers displayed high levels of stromal TGFβ activity, as indicated by the presence of phosphorylated SMAD3 (pSMAD3) (Fig. 1f and Extended Data Fig. 2b ) and expression of CALD1 and IGFBP7 (Extended Data Fig. 2c, d )-two TGFβ -induced genes expressed in cancer-associated fibroblasts (CAFs) that predict poor prognosis 4 . These genetic CRC models therefore reproduce key features of the tumour microenvironment (TME) in advanced human CRCs.
We collected fresh samples from multiple primary mouse tumours or metastases and established a mouse tumour organoid (MTO) biobank (Fig. 1g) . Quadruple-mutant LAKTP MTOs expanded in vitro independently of factors that stimulate WNT, EGF and TGFβ pathways ( Fig. 1h and Extended Data Fig. 3 ). When injected into the caecum wall of syngeneic C57BL/6J recipients, these MTOs engrafted with a success rate of 10 out of 32 (31%) and progressed to fully invasive T3-T4 tumours (Extended Data Fig. 4a, b) . Forty per cent of engrafted MTOs produced overt liver metastatic disease. We observed prominent T-cell exclusion and increased TGFβ activity in the TME in primary tumours from orthotopically transplanted LAKTP MTOs (Extended Data Fig. 4c-f ). TGFβ -activated stroma is a defining feature of poor prognosis consensus molecular subtype 4 (CMS4) 7 . Transcriptomic classification indicated that LAKTP MTOs displayed the CMS4 phenotype when transplanted in the caecum of syngeneic mice, but not when cultured in vitro (Fig. 1i and Extended Data Fig. 5 ). We obtained similar results with triple-mutant MTOs. These findings confirm that stromal gene expression is required to identify poor prognosis molecular subtypes 4, [17] [18] [19] (see Supplementary Discussion). Similar to microsatellite-stable (MSS) human CRCs 20 , triple-and quadruple-mutant MTOs accumulated between 0.5 and 3.5 nonsynonymous coding mutations per megabase (Extended Data Fig. 6a, b) , which indicates that the genomes of these tumours evolved extensively. The most prevalent mutational signature in MTOs was signature 1, characteristic of MSS CRCs 21 (Extended Data Fig. 6c ). MTOs and human MSS CRCs also displayed similar numbers of predicted high-affinity MHC-I-binding neoantigens, whereas mouse CRC cell lines CT26 and MC-38 exhibited around 40 times this number (Fig. 1j ). Experimental liver colonization by MTOs caused an increased metastatic burden in the nu/nu background compared to wild-type C57BL/6J mice ( Fig. 1k) , indicating that the tumours were susceptible to T-cell-mediated adaptive immunosurveillance. Indeed, micrometastases were characterized by abundant CD3 + T cells intermingled with tumour cells (Fig. 1l) . Notably, T cells were progressively excluded at later time points (Fig. 1l, m) .
Cell-population profiling of human or mouse CRC samples revealed that CAFs were the main contributors to TGFβ production (Extended Data Fig. 7a, b) . We made use of the TGFBR1-specific inhibitor galunisertib 22 to inhibit TGFβ signalling in the TME. Treatment with galunisertib starting 11 days after transplantation of LAKTP MTOs in the caecum of syngeneic mice reduced primary tumour size, reduced the extent of carcinomatosis and blocked the appearance of liver metastases (Fig. 2a) . Immunohistochemical quantification showed that galunisertib reduced the number of pSMAD3 + cells (Fig. 2b ) and gene expression profiling demonstrated decreased levels of TGFβ -response signatures 6 in fibroblasts (F-TBRS) and T cells (T-TBRS) (Fig. 2c ). To directly test therapeutic effects on liver metastatic disease, we inoculated LAKTP MTOs derived from either primary CRCs or liver Classi er score 
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Figure 1 | Analysis of compound mutant mouse models and MTOs. a, Combination of alleles used to generate mouse models; dashed line distinguishes strains along the linear progression model 8 of A-K-T-P from other combinations of mutations. b, Classification of tumours according to the AJCC-TNM system, ranging from carcinoma in situ or adenoma (T is /Ad) to four levels of increasingly invasive cancers (T1-T4, see Methods). c, Worst T-phenotype diagnosis per mouse, number of mice is indicated in the circles. The thick lines indicate the linear progression sequence. d, Metastasis in LAKTP mice. Outer ring, associated type of primary cancer. e, Box plot of T-cell density in normal mucosa (NM) and adenoma (Ad), compared to double-mutant (LAK, LAT and LAP, 2× ), triple-mutant (LAKT, LAKP and LATP, 3× ) and quadruple-mutant (LAKTP, 4× ) cancers. n = 119, 242, 7, 8 and 16 regions of interest (ROIs), left to right. Right, CD3 immunohistochemistry of a LAKTP T4 carcinoma (CA), arrowheads indicate CD3 + cells. Box plots have whiskers of maximum 1.5 times the interquartile range; the boxes represent first, second (median) and third quartiles. f, Box plot of pSMAD3 + cell density in normal submucosal tissue (NSM), compared to 2× , 3× and 4× cancers, n = 37, 5, 10 and 16 ROIs, left to right. Right, pSMAD3 immunohistochemistry of a LAKTP T4 carcinoma, arrowheads indicate pSMAD3 + cells. Two-sided Welch's t-test (e, f). g, MTO biobank and isograft technology. h, Mean sensitivity of MTOs to niche factors. WT, wild type. i, Left, cross-validation of consensus molecular subtype 4 (CMS4) classifier on human CRCs. Patients (shown as vertical bars) are ranked by subtype on the basis of classifier score. Right, classifier applied to 3× and 4× mutant MTOs in vitro (grey, n = 5 and 3, respectively) and to orthotopic isografts of those MTOs (orange, n = 2 and 3). j, Predicted MHC-I neoantigens in MTOs (n = 6 and 10, left and right, respectively), human CRCs (n = 266 and 112, left and right, respectively) and mouse CRC cell lines (n = 2). k, Liver metastasis generated by 4× MTOs in C57BL/6J or nu/nu mice (n = 10, 5, 11, 5, 10 and 5 mice, left to right; mean ± s.e.m.; two-sided Mann-Whitney U-test). l, CD3 immunohistochemistry on MTO129 liver metastases (Met) at the indicated days after intrasplenic injection. Micromet, micrometastasis. m, CD3
+ cell densities (individual metastases in grey and mean for mice in black; bars, group means ± s.e.m.); analysed with a mixed-effects linear model; n = 4, 3, 3, 2 and 2 mice, and n = 39, 58, 71, 56 and 56 tumours, left to right. Scale bars, 500 μ m.
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metastases in the portal circulation; the latter exhibited enhanced metastatic capacity (Extended Data Fig. 6e ). Treatment with galunisertib markedly decreased metastatic burden for all MTOs (Fig. 2d and Extended Data Fig. 6f ), effectively curing a large proportion of mice (Fig. 2e) . Galunisertib blocked TGFβ signalling in the TME of meta stases (Extended Data Fig. 7c-h ). We also transplanted LAKTP MTOs in mice bearing floxed Tgfbr2 alleles that express a ubiquitous CreERT2 recombinase (UBC ). Tamoxifen treatment induced recombination in fibroblasts, endothelial cells and leukocytes, and inhibi ted metastasis formation by isografted MTOs (Fig. 2f, g and Extended Data Fig. 8a ). To analyse triple-mutant MTOs in vivo, we inocu lated large numbers of cells. Four out of six tested MTOs (two LAKP and two LAKT) gave rise to metastases. However, these liver tumours remained very small (Extended Data Fig. 6g ), possibly owing to niche factor dependencies 9, 11, 19 . Nevertheless, galuni sertib treatment reduced liver metastases generated by LAKP MTOs (Fig. 2h and Extended Data Fig. 8b, c) . We also introduced loss of function Smad4 mutations (S) in LAKP MTOs using CRISPR-Cas9 technology. In vitro, LAKPS MTOs were resistant to the cytostatic action of TGFβ (Fig. 2i, j) . In vivo, LAKPS formed larger numbers of liver tumours that were also larger in size than those formed by parental LAKP MTOs. Galunisertib effectively abrogated the metastatic capacity of LAKPS MTOs and, importantly, ; right, median number ± 95% confidence interval; n = 21 mice per condition, two-sided Mann-Whitney U test. b, pSMAD3 + cell density (mean ± s.e.m.) in primary carcinomas (n = 9, 7); two-sided Student's t-test. c, Expression levels of TBRS in primary CRCs. Tukey box plots, n = 6 tumour samples, two-sided Mann-Whitney U test. d, Liver metastases (mean ± s.e.m.) generated by MTOs, treated with vehicle or galunisertib; n = 5, 5, 5, 5, 15, 17, 12, 12, 20 and 25 mice, left to right; analysed with a mixed-effects linear model. Exp. LiM, experimental liver metastasis; LiM2, second-round experimental liver metastasis. e, Representative livers at end point, arrows point to metastases. Kaplan-Meier survival curve of mice treated as in d. Control, n = 41 mice; galunisertib, n = 35 mice; Mantel-Cox test. f, Liver metastases (mean ± s.e.m.) in UBC creERT2 ;Tgfbr2 fl/fl mice, recombined (n = 9) or not (n = 6). g, Liver tumours from f, stained for the recombination marker GFP, representative of three experiments. Scale bars, 1 mm. The graph shows the percentage of GFP + cells (mean ± s.e.m.). h, Liver metastases (mean ± s.e.m.) generated by 3× LAKP MTOs. n = 15 and 14 mice, left and right, respectively; two-sided Mann-Whitney U test. i, Western blot for SMAD4 and actin of LAKP empty guide (EG)-or CRISPR-targeted (#1 and #2) Smad4 KO organoids. j, LAKP or LAKPS organoids. (mean ± s.e.m., n = 4 technical replicates) in control medium or treated with TGFβ 1. k, Liver metastases (mean ± s.e.m.) from LAKP (EG) and LAKPS (guide #1) MTOs. Gal, galunisertib; x, diameter. n = 5 mice per condition; two-sided Mann-Whitney U test. Right, tumour diameters with s.e.m., n = 10 mice per condition.
did not enhance growth of metastases generated by LAKP MTOs with wild-type TGFβ pathway ( Fig. 2k and Extended Data Fig. 8d) .
To study the kinetics of metastasis, we transduced MTOs with luciferase, which did not modify the therapeutic efficacy of galunisertib (Extended Data Fig. 8e ). Bioluminescence revealed that galunisertib markedly enhanced cell killing at the onset of the exponential growth phase. However, this did not occur in nu/nu mice (Extended Data Fig. 8f-h ). These kinetics are suggestive of an adaptive anti-tumour immune response. Indeed, the therapeutic effect of galunisertib was abolished upon depletion of CD8 + cytotoxic T lymphocytes (CTLs) (Fig. 3a, b) or CD4 + T-helper (T H ) cells (Extended Data Fig. 8i ). We also transplanted MTOs in mice from the colony used to generate the original compound mutant mice. Galunisertib decreased metastatic burden in these hosts (Extended Data Fig. 8j ), indicating that immunological rejection was not due to expression of exogenous antigens in MTOs such as those encoded by eGFP and creERT2 transgenes.
We next assessed the status of the adaptive immune system in a transcriptomic dataset of human MSS CRC samples (n = 981) by measuring levels of expression signatures specific for naive or T H 1-activated CD4 + T cells. Microsatellite-instable (MSI) CRCs displayed increased ratios of T H 1-to-naive T-cell genes, consistent with previous observations 23 (Extended Data Fig. 9a ). In MSS CRCs, the ratio of T H 1 to naive cells was inversely correlated to the mean expression of TGFB1, TGFB2 and TGFB3 genes or the CAF-specific gene expression program (Extended Data Fig. 9b-f ) and predicted disease relapse (Extended Data Fig. 9d, g ). Therefore, abrogated T-cell differentiation, and increased TGFβ and CAF gene expression characterize a substantial subset of patients with MSS CRC and a poor prognosis.
Flow-cytometry analyses on whole livers colonized by MTOs for 7-10 days showed that there was increased recruitment of CD3 + and CD4 + cells after galunisertib treatment (Fig. 3c ). This finding was confirmed by immunohistochemistry-based quantifications of liver sections, which also revealed an increased presence of T-bet, the master transcription factor regulating T H 1 cell differentiation (Extended Data Fig. 9h, i) . Equivalent observations were made in treated liver meta stases from parental MTOs, in experiments with orthotopic implantation, and during genetic abrogation of TGFβ signalling in the TME (Extended Data Fig. 10a-c ). Importantly, both T H cells and CTLs underwent activation, indicated by the increase in CD44 +
CD62L
− and CD69
− populations (Fig. 3c, d ), increased levels of T-bet and IFNγ effector molecules in T H cells, and increased GZMB production and expression of proliferation genes in CTLs (Fig. 3e, f) . We hypothesized that this robust immune response might immunize mice against the tumour cells. When survivors were rechallenged with the same MTO, most tumours were rejected within two weeks in the continued absence of treatment, whereas the MTOs grew efficiently in naive C57BL/6J recipients. Concurrent depletion of CD8 + CTLs inhibited tumour rejection (Fig. 3g) . We conclude that increased TGFβ levels in the TME limit adaptive immune responses by inhibition of the T H 1-effector cell phenotype.
Finally, we assessed the therapeutic action of galunisertib in mice with overt metastatic disease. Galunisertib treatment 14 days after MTO inoculation reduced metastatic burden but resulted in few complete remissions (Fig. 4a) . Nevertheless, we observed increased infiltration of CD4
+ T cells and of T-bet + lymphocytes immediately after initiation of therapy (Extended Data Fig. 10d ). Exploring resistance mechanisms to explain this mild response, we discovered that galunisertib-activated T cells exhibited marked surface expression of programmed cell-death protein 1 (PD-1) (Fig. 4b) , and that metastases generated by MTOs progressively recruited stromal PD-1 ligand 1 (PD-L1)
+ cells-most Letter reSeArCH prominently tumour-associated macrophages-as they expanded in size (Fig. 4c, d and Extended Data Fig. 10e, f) . Treatment of mice bearing overt metastatic disease with anti-PD-L1 therapy alone had a very modest therapeutic effect (Fig. 4e) . However, combined treatment with galunisertib and anti-PD-L1 antibodies induced a pronounced immune response, with increased T-bet and IFNγ levels in CD4
+ T H cells and increased GZMB production in CTLs, which eradicated most metastases and prolonged recurrence-free survival for over a year after cessation of treatment ( Fig. 4e-g ). This response was associated with a marked, synergistic increase in infiltrating lymphocytes and T-bet expression (Fig. 4h, i ), indicating both a disruption of the T-cellexclusion phenotype characteristic of progressed metastatic disease and prominent T H 1 immune activation.
It has been hypothesized that MSS CRCs are immunologically 'cold' , that is, scarcely T-cell infiltrated and possibly non-immunogenic, and that they are therefore unlikely to benefit from immune therapies 24 (Supplementary Discussion). By contrast, our data reveal that this class of CRCs can be killed effectively by the adaptive immune system through a CTL-dependent process, which CRC cells avert by increasing TGFβ levels. Consistent with the well-established role of TGFβ signalling in suppressing differentiation and activity of T cells [25] [26] [27] [28] , we observed that a TGFβ -activated TME antagonizes the T H 1-effector cell phenotype. We also show that such a TME excludes T cells from tumours, a phenomenon associated with poor outcomes across cancer types 3, 29, 30 . Enabling immune infiltration using TGFβ inhibitors is sufficient to confer susceptibility to anti-PD-1-PD-L1 checkpointbased therapies, a strategy that may have broad applications for treatment of cancers that grow in a TGFβ -rich environment. These results strongly suggest that inhibition of TGFβ signalling could be promising as immunotherapy for patients with MSS, stroma-rich CRCs and a poor prognosis.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. + leukocytes in liver metastases (mean ± s.e.m.) at indicated days after injection, or in non-injected (NI) liver, n = 4, 5, 5, 6 and 3, left to right. e, Treatment from day 14 of established liver metastases. Left, mean number of liver metastases ± s.e.m., n = 11, 13, 12 and 14 mice, left to right; two-sided Mann-Whitney U test; right, Kaplan-Meier survival curve; n = 6 (vehicle + IgG), 7 (galunisertib + IgG), 6 (vehicle + anti-PD-L1), 7 (galunisertib + anti-PD-L1), Mantel-Cox test. f, g, Surface activation markers (f) and intracellular markers (g) in mice euthanized two days after start of treatment (day 16). Mean percentage ± s.e.m., n = 6, 7, 6, 7 mice, left to right; two-sided Student's t-test. h, Cell densities quantified by immunohistochemistry from mice in e. Individual metastases in grey, mouse means in coloured squares; bars show group means ± s.e.m., n = 5, 4, 4 and 4 mice, left to right; analysed with a mixedeffects linear model. i, Images from the analysis in h; mean cell densities are indicated. Scale bars, 500 μ m. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001. 
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Ethics and animal maintenance. All experiments with mouse models were approved by the Animal Care and Use Committee of Barcelona Science Park (CEEA-PCB) and the Catalan government. Mice were maintained in a specific-pathogen-free (SPF) facility with a 12-h light-dark cycle and given ad libitum access to standard diet and water. All mice were closely monitored by the authors (D.V.F.T. and S.P.-P), facility technicians (during treatments) and by an independent veterinary scientist responsible for animal welfare. 31, 32 . The latter allele allowed us to detect recombination using the shift from tdTomato to eGFP expression. Recombination of genetic models. To induce tumorigenesis from mutated intestinal stem cells (ISC) with preferred localization in the distal part of the intestine, adult mice (at 12-13 weeks of age) were given drinking water (ad libitum) containing 2.5-3% (w/v) dextran sodium sulfate (DSS) for five days, and two intraperitoneal injections of diluted (4 mg/kg) tamoxifen (Sigma; dissolved in sunflower oil with 0.5% ethanol) on days 0 and 5. Thirteen per cent of mice treated in this way died in the first two weeks, most likely owing to DSS toxicity. These mice were excluded from the analysis. Animal weight, stool type and overall appearance were scored two times per week. With increasing morbidity, mice were evaluated more frequently until the experimental end point: progressive or rapid weight loss or emaciation and poor physical appearance, characterized by anaemia, hunched posture, ungroomed appearance and lethargy. Mice were then euthanized and dissected; the wall of the peritoneum was inspected and intestines, mesentery, liver, spleen, kidneys, diaphragm and lungs were collected. After macroscopic and/or binocular analysis, tissues were washed in phosphate-buffered saline (PBS), fixed in 10% formalin solution (Sigma) overnight and embedded in paraffin. Survival statistics were analysed using GraphPad Prism software (v.7.03). Median latency of metastasis was obtained by taking the median survival time of the animals in which metastases were detected.
Although the DSS-treatment-mediated induction of inflammation is acute and subsides after 2-3 weeks, we also induced gene recombination with tamoxifen without DSS treatment. Without this acute inflammation, induction still gave rise to tumours equivalent to those described here (including invasive carcinomas). However, tumour burden tended to concentrate to the distal ileum (small intestine), leading to adenomatous carpets, causing serious complications for the mouse, including reduced life span. The benefit of DSS is that it helps to target the colon. The experiments without DSS are not included in the survival and tumour assessment of this study.
Recombination on the UBC creERT2 ;Tgfbr2 fl/fl background was performed with two shots of 80 mg/kg tamoxifen on days two and three. One mouse was excluded from the analysis shown in Fig. 2f because it exhibited no recombination upon tamoxifen treatment. Histology and immunohistochemistry. Standard haematoxylin and eosin and antibody staining were performed on 4-μ m tissue sections using standard procedures, as described previously 4 . Antibodies against CALD1 (rabbit; Sigma HPA008066; 1:250), IGFBP7 (rabbit; Sigma HPA002196; 1:200), pSMAD2 (rabbit; Cell Signaling 3108; 1:50), CD4 (rabbit; Sino Biological 50134-R001; 1:1000), CD8 (rabbit; Biorbyt orb10325-200; 1:200), FoxP3 (rabbit; Abcam ab54501; 1:1000), T-bet (Santa Cruz sc-21003; 1:500), pSMAD3 (rabbit; Abcam ab52903; 1:500) and PD-L1 (Cell Signalling 16764988S; 1:25) were used for staining overnight at 4 °C. Antibodies against GFP (rabbit; Life Technologies A11122; 1:500) and CD3 (rabbit; DAKO IS50330; 1:30) were used for staining for 2 h at room temperature. Images of histology and immunohistochemistry were taken with a Nikon Eclipse E600 and Nikon DS-Ri1 camera or with a Hamamatsu NanoZoomer Digital Slide Scanner (20× magnification). Histopathological quantifications. Haematoxylin-and eosin-stained sections of intestines were scored blindly for T (tumour) status by an expert pathologist (M.I.) and a second observer (D.V.F.T.) using the AJCC-TNM system: scoring for T is (carcinoma in situ), T1 (adenocarcinoma with submucosal invasion), T2 (intramuscular invasion), T3 (transmuscular invasion; serosa intact or cannot be evaluated) or T4 (transserosal invasion; T4b when local metastasis is evident, otherwise T4a). Across all genotypes, 156 tissue samples were scored (both small intestine and large intestine: caecum, colon and rectum) from 68 mice across eight genotypes. Given the high expression of Lgr5 in the distal ileum and caecum, these tissues were in some cases overgrown with a carpet of dysplastic tissue, making adenoma counting impossible. However, we observed no obvious correlation between the percentage of dysplastic small-intestine surface and genotype. All invasive adenocarcinomas (small and large intestine) and large intestine adenomas were counted individually, reaching a total count of 1,477 tumours. Mouse tumour organoid generation and culture. Before tissue fixation, tumours were dissected to include potential submucosal invasion and washed in PBS. Dissected material was roughly chopped with razor blades, followed by enzymatic digestion with 200 U/ml collagenase IV in DMEM (Life Technologies) for 20 min at 37 °C. Tissue fragments were subsequently treated by mechanical disruption in DMEM with 10% FBS (Life Technologies), washed with cold PBS and filtered through 100-and 40-μ m meshes. Single-cell preparations were stained with propidium iodide (PI, a membrane integrity marker) and GFP + PI − cells were sorted in a FACS Aria flow cytometer (BD Biosciences). Typically, around 1,000 cells were obtained and plated in a drop of cold basement-membrane extract (BME) medium (Cultrex BME Type 2, Amsbio): 40 μ l in a prewarmed (37 °C) well of a standard 24-well plate (Corning). After 5 min, mouse tumour organoid culture medium (advanced DMEM/F12, supplemented with 10 mM HEPES, Glutamax, B-27 without retinoid acid (all Life Technologies), 50 ng/ml recombinant human EGF (Peprotech), 100 ng/ml recombinant human NOGGIN and 1 μ M galunisertib (LY2157299, see below)) was added. NOGGIN was produced in house; expressed as a His-tagged protein in HEK293-6E cells and purified with a 5-ml nickel-affinity column and a 5-ml HisTrap HP column in an ÄKTAxpress at 4 °C. Protein fractions were pooled and desalted (HiPrep 26/10 column), and tested on mouse Apc-mutant adenoma organoids or on bone morphogenic protein (BMP)-sensitive patient-derived organoids, analysing ID1 and ID3 gene expression by quantitative PCR. In initial passages, MTO medium was supplemented with the antimicrobial reagent Normocin (InvivoGen). MTOs were cultured at 37 °C with 85-90% humidity, atmospheric O 2 and 5% CO 2 .
For MTO passaging, basement-membrane extract drops were washed once with HBSS (Lonza) and treated with Trypsin-EDTA (Sigma) for 20 min at 37 °C, followed by mechanical disaggregation of organoid fragments (by pipetting) until a single-cell suspension was obtained. Trypsin was quenched with FBS, cells were washed with HBSS and replated in cold BME medium on warm plates. MTOs were frozen as trypsinized organoids (single cells or small clusters) in DMEM with 50% FBS and 10% DMSO (Sigma). Cultures were checked bimonthly for mycoplasma contamination. CRISPR genome editing. For gene knockout, guides were designed and cloned into px330-U6-Chimeric BB-CBh-hSpCas9 (Addgene: #42230), which was modified by introducing a SV40 promoter-IRFP expression cassette downstream of hSpCas9. Guide sequences (sgRNA indicated in upper case, restriction overhang in lower case):
Smad4: #1 forward, caccgAGACAGGCATCGTTACTTGT and reverse, aaacACAAGTAACGATGCCTGTCTc; Smad4: #2 forward, caccgAGTTTGATGTG TCATAGACA and reverse, aaacTGTCTATGACACATCAAACTc; mCherryLuc: forward, caccGCGCATGAACTCCTTGATGA and reverse aaacTCATCAAGG AGTTCATGCGC.
Organoids were nucleofected using a Nucleofector 2b (Lonza) in combination with the Cell Line Nucleofector Kit V (Lonza). Organoids were trypsinized for 15 min at 37 ºC to generate single cells (1.0-1.5 × 10 6 cells per guide), which were resuspended in 100 μ l nucleofection buffer mix containing 3 μ g sgRNA and nucleofected using program A32. Subsequently, cells were plated in BME medium and cultured in full growth medium. For Smad4 knockout mutants, three days after nucleofection, growth medium was exchanged for selection medium (+ TGFβ 1). Selection of mCherry-Luc knockout mutants was achieved by FACS sorting of IRFP-mCherry double-negative cells twice. Western blotting. Trypsinized MTO cell pellets were resuspended in lysis buffer (1 mM EDTA, 1 mM EGTA, 1% SDS) containing protease inhibitor cocktail (Sigma). Protein concentration was determined using a standard Bradford assay (BioRad) and 30 μ g per sample was separated by SDS-PAGE and transferred to a PVDF membrane (Millipore). Membranes were incubated with antibodies in TBS-Tween (0.2%) containing 5% milk at room temperature for 1 h. Antibodies against SMAD4 (B-8; Santa Cruz sc7966) and actin (Abcam ab20272) were used. The secondary antibody was horseradish peroxidase (HRP)-conjugated goat antimouse IgG (Pierce 31430). Immunohistochemical quantifications. Scanned CD3, CD4, CD8, FoxP3, T-bet and pSMAD3 immunohistochemistry stainings were analysed in QuPath (v.0.1.2) using the positive cell detection feature with empirical parameters. Several ROIs (tumours) were taken per section. In cases in which multiple sections per mouse or liver were considered, care was taken to avoid quantifying the same tumour more than once. Data were processed and visualized with R and RStudio 33 (v.3.4.2 and v.1.1.383, respectively) For both mouse and human data, neoantigens were predicted using netMHCpan software (v.2.8). See Supplementary Methods for a detailed description. Mouse injections. For all injections, C57BL/6J (or athymic BALB/c nu/nu) mice were purchased from Janvier Labs at six weeks of age and injected at seven weeks. Sex was matched with the origin of the tumour. Intrasplenic or portal vein injections were used for liver colonization by the introduction of dissociated organoids (single cells) into the portal circulation; MTOs were cultured in standard six-well plates for four days and trypsinized as described in 'Mouse tumour organoid generation and culture' . The resulting cell suspension was filtered through 100-and 40-μ m meshes (to remove clumps of cells and aggregated debris). Cells were counted and suspended in HBSS for injection, using 2-5 × 10 5 cells in 70 μ l per mouse. Intrasplenic injections were performed as previously described 4, 6, 35 . For portal vein injections, a 30G syringe was used to inject 100 μ l of cell suspension directly into the portal vein. Mice were euthanized at 3-5 weeks, visible liver metastases were counted and data were analysed using GraphPad Prism software (v.7.03). For subcutaneous injections, MTOs were cultured in standard six-well plates for three days and recovered with Cell Recovery Solution (BD Biosciences) for 40 min on ice. Organoids were washed in HBSS and a 10% fraction was trypsinized for cell counting (Neubauer or TC20 automated cell counter, Bio-Rad). Organoids were suspended in HBSS with 30% BME, an equivalent of 1.5 × 10 5 cells was injected in 2-4 locations on the flanks of each mouse. Growth was scored by palpation and volume was measured with a caliper (multiplying three orthogonal diameters and dividing by two) twice per week. In accordance with our IACUC protocol, mice with tumours over 300 mm 3 in volume were euthanized. Intracaecum injections were used for orthotopic isograft formation: MTOs were recovered as for subcutaneous injection, and an equivalent of 5 × 10 5 cells in 11 μ l was injected per mouse. Intracaecum injections were performed using a 30G needle under binocular guidance, adapting the protocol used in ref. 36. Mice were euthanized ten weeks after injection and metastasis was scored macroscopically as well as histologically. Alternatively, orthotopic primary tumours were generated by transplantation of a 1-mm 3 piece of subcutaneously grown MTO-derived tumour (for example, for 3× MTO orthotopic transplantation); the piece was sutured on the tip of the caecum, which was folded over itself to mitigate carcinomatosis. Post-injection, all mice received analgesia (buprenorphine). The caliper technique was used to measure orthotopic tumour sizes after mice were killed. After measurement, pieces were dissected from fresh tumours and lysed in TRIzol (Life Technologies). RNA was purified with the Ambion PureLink kit (Life Technologies). Mouse treatments. Galunisertib (also known as LY2157299) was synthesized in house and prepared as previously described 6 . Galunisertib or vehicle control was administered by gavage in a 0.15 ml volume, twice per day, starting two days after cell injection for metastasis-initiation experiments, unless otherwise indicated (treatments starting two days after injection give identical results to pre-treating two days before injection). A 800 mg/kg dose per treatment was used for all experiments except for the treatment of MTO138, or for the prolonged treatment of orthotopically implanted mice, in which 400 mg/kg doses were used. For in vivo CD8 + T-cell depletion, rat CD8α (YTS 169.4; BioXCell BE0117) or rat IgG2b (LTF-2; BioXCell BE0090) isotype-control antibodies were diluted to 1 mg/ ml in PBS and 200 μ l was administered per mouse by intraperitoneal injection on days − 1, 6 and 13 (unless otherwise indicated) relative to the day of MTO injection. For CD4
− T H cell depletion, rat anti-CD4α (GK1.5; BioXCell BE0003-1) or rat IgG2b isotype-control antibodies were used. For checkpoint immunotherapy or dual immunotherapy, we used rat PD-L1 (10F.9G2; BioXCell BE0101) or rat IgG2b (LTF-2; BioXCell BE0090) isotype-control antibodies. In vivo study design. Experimental group sizes were practically associated to cage sizes (five mice per cage) and treatment experiments were designed to have n ≥ 5 mice per group (one or more cages). No mice were excluded from the analysis, unless explicitly indicated in the Methods. For gavage (galunisertib) treatment, as vehicle control and galunisertib are visually distinguishable, the only randomization we performed was the order of injecting mice: the researcher performing the injections was blinded to the treatment group. End-point criteria are equivalent to those described in 'Recombination of genetic models' . For genetic models, littermates were used as controls and cohorts were accumulated over time for logistical reasons. Mice were excluded if no tumours were observed after a year of survival post-induction. Statistics and reproducibility. When no statistical control for confounders was needed, numbers of metastases in each condition were compared using a twosided Mann-Whitney U test with exact computation of the null hypothesis, as implemented in the wilcox_test function in the R 33 coin package 37 or in GraphPad Prism. For Fig. 2d , where data were derived from different experimental runs and/ or the same treatment performed on multiple MTOs, a mixed-effect linear model was fitted in which experiment run and/or MTO were included as a random effect.
In immunohistochemical experiments and the FACS experiment shown in Fig. 3c , group mean differences were assessed using a linear model. When the data involved more than one MTO (Fig. 3c and Extended Data Figs 9h and 10a) or more than one experiment run (Extended Data Figs 9h and 10c) , these variables were included in the models as covariates. When multiple observations per mouse were derived, a mixed-effects linear model was fitted that included the mouse as a random effect (Figs 1m, 4h and Extended Data Figs 9h, 10a, c, d) ; otherwise, a standard linear regression model (only fixed effects) was used for analysis (Extended Data Fig. 10b) .
In all cases, a fourth root was used to transform the outcomes in order to fulfil the assumptions of the linear models. Immunohistochemical quantifications: besides plotting individual tumours (grey), results were represented at the mouse level (coloured or black squares or MTO-dependent symbols) and at group level using the adjusted means and standard error of the means derived by the models in their original scale, after undoing the transformation. To achieve this, standard error of the means were computed by simulation from the corresponding model 38 . Wald tests derived from the linear models were used to perform pairwise comparisons between experimental conditions. A 5% level was chosen for statistical significance. All the analyses were performed using R
33
. Mixed-effects models were fitted using the R packages lme4 39 and lmerTest 40 . For the Kaplan-Meier survival curve after galunisertib treatment (Fig. 2e) , all censored mice were metastasis-free when killed. Some mice were euthanized at the end point of control mice (severe morbidity), in order to count nodules at the same time point. Metastasis-burdened mice (≥ 1 tumour) were scored as death events, whereas disease-free mice were censored from the plot (ticks, zeroes in Source Data).
Tukey box plots in Figs 1e, f, j, 2c 3c and Extended Data Figs 3d, 7a and 9a-c, have whiskers of maximum 1.5 times the interquartile range; the boxes represent first, second (median) and third quartiles. In Fig. 1c , P values for comparison of phenotype severity, defined as severe (T3 or higher) versus less severe (< T3), are 0.0002 for LAKTP versus combined 3× genotypes, and < 0.0001 for LAKTP versus combined 2× genotypes and for LAKTP versus LA (Fisher's exact test). We also tested for the presence (≥ T1) or absence of carcinomas and the P values for these comparisons are: 0.0013 for LAKTP versus 3× , 0.0005 for LAKTP versus 2× , and < 0.0001 for LAKTP versus LA (Fisher's exact test). The immunohistochemistry images in Fig. 1e , f are representative of four independent experiments. In Fig. 1i . Data are from ten independent experiments. In Fig. 2e , data are from seven independent experiments, using either MTO129 or MTO138. In Fig. 2h , data are from MTO54 and MTO220, combined. Figure 2i , j, using MTO220, is representative of two independent experiments. Western blot source data are shown in Supplementary Fig. 1 . In Fig. 2k , right, the values are fraction of total ± s.e.m. Data are from experiment with empty guide or from guides #1, #2 LAKP and S combined, from two independent experiments. The experiment in Fig. 3a was performed with MTO138, and the experiment in Fig. 3b was performed with MTO129. In Fig. 3g , P values refer to the comparison between: anti-CD8 and IgG in the survivors (P = 0.0043); rechallenge IgG and naive IgG, and between rechallenge IgG and naive anti-CD8 (P < 0.0001); twosided Mann-Whitney U test. Figure 4b , c are representative of two experiments. In Fig. 4d , MTO129 is injected. In Fig. 4f , P values are for CD4 and CD62L: 0.0002 (control versus galunisertib) and 0.0051 (control versus double); CD44: 0.0008 (control versus galunisertib) and 0.0297 (control versus double); CD8 and CD62L: 0.0159 (control versus galunisertib) and 0.0181 (control versus double). In Fig. 4g , P values are for CD4 and IFNγ : 0.0099 (control versus galunisertib) and < 0.0001 (control versus double); T-bet: 0.0208 (control versus galunisertib) and 0.0017 (control versus double); CD8 and GZMB: 0.0054 (control versus galunisertib) and 0.0001 (control versus double). For Fig. 4h , all P values are listed in Source Data. The experiment in Fig. 4i was performed once. Patient data analysis. We used five publicly available Affymetrix microarray datasets from the NCBI GEO repository, which include gene expression and
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clinical information from a total of 1,194 patients with CRC. In order to obtain CD4-naive and CD4
+ T H 1 profiles, we carried out a differential expression analysis on gene expression dataset GSE22886
41
. We defined the CD4 naive signature to include genes that are upregulated at least threefold in both CD4-naive versus T H 1 and in CD4-naive versus Th2; Benjamini-Hochberg false discovery rate 42 (FDR) < 5% in both comparisons. Similarly, the CD4-T H 1 signature included genes that were upregulated at least threefold compared to CD4-naive, and limma FDR < 5%. Association with metastasis was evaluated using a frailty Cox proportional hazards model. Statistical significance was assessed by means of a log-likelihood ratio test, and Wald tests were used for pairwise comparisons when necessary. Association of expression intensities was evaluated as continuous variables assuming a linear relationship with the logarithm of the relative risk. Sample groups of low, medium and high expression levels were defined using the tertiles of the intensity distribution after correction for technical effects. For visualization purposes, Kaplan-Meier curves were estimated for groups of tumours showing low, medium and high gene or signature expression. Only samples from patients diagnosed in stages I, II and III were taken into consideration for these analyses. The threshold for statistical significance was set at 5%. All analyses were carried out using R 33, 43 . See Supplementary Methods for a detailed description. Classification of mouse tumours according to consensus molecular subtypes. We used the k-top scoring pairs (k-TSP) algorithm and trained the classifier for a binary outcome (CMS4 versus not-CMS4) in 960 samples. See Supplementary Methods and Extended Data Fig. 5 for a detailed description. Data availability. MTO whole-exome sequencing and RNA sequencing analysis (RNA-seq) data have been deposited in the ENA archive with accession number PRJEB22559. Expression array data are available at GEO with accession number GSE103562. Computer code is available upon request. Source Data are available in the online version of the paper. Arrows indicate invasive cells or glands, absent in an adenoma (d), restricted to the mucosa in an in situ tumour (Tis, e), breaching the muscularis mucosae (MM) in a submucosal invasive tumour (T1, f), penetrating the muscle layer (ML) in an intramuscular invasive tumour (T2, g), reaching the serosa layer beyond the ML in a submuscular invasive tumour (T3, h), or infringing all layers including the serosa in a subserosal or T4 tumour (i). j, Representative micrograph of an haematoxylin-and eosin-stained invasive subserosal adenocarcinoma (T4) of an LAKTP mouse. Carcinoma (CA) glands are indicated, invading through the muscle layer (ML). k-n, Examples of spontaneous metastases (Met) in the mesentery, diaphragm, liver and lung of induced LAKTP mice, each image is representative of two experiments. Scale bars, 500 μ m. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined. Experimental group sizes were practically associated to cage sizes (5 mice/cage) and treatment experiments were designed to have n >= 5 per group (1 or more cages) .
Data exclusions
Describe any data exclusions.
In the DSS/tam induction of the genetic model, 13% of mice died in the first 2 weeks from DSS treatment and were excluded from analysis. One mouse was excluded from the Fig. 2f because it showed no recombination upon tamoxifen treatment.
In the KM survival curve in Fig 2e, some cohorts of mice (Con and Gal) were sacrificed at endpoint of Con (metastasis-associated severe morbidity) for tumour nodule count. Fully cured Gal mice that were culled this way were censored from the survival plot (ticks).
Replication
Describe whether the experimental findings were reliably reproduced.
All experiments were reproducible.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Because daily drug treatments were given as one type per cage (to avoid confusion and errors), we found the best way to randomize was to inject mice with tumour organoids in semi-random order: balanced among the predetermined treatment arms so as to not have any difference in cell viability but otherwise unpredictable to the person doing the injection.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
T (tumour) status scoring from H&E stained sections was performed by two blinded observers. As stated above, the investigator doing the injection was blinded to treatment arm. In addition, the technicians doing the daily drug administrations were blinded to the experiment design including groups. Data collection and analysis was not blinded.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.) A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
We used R (v3.4.2), RStudio (v1.1.383) and FIJI/ImageJ (v1.51d), and have custom codes that are available upon request. In addition, we used QuPath (v0.1.2), GraphPad Prism (v7.03), netWHCpan (v2.8), bwa (v bwa-0.7.4), Sambamba (v0.5.9), Picard (v1.128), GATK (v3.5), snpEff (v4.1), deconstructSigs (c1.8.0), Star (v2.3.0e), GeneAtlas, FlowJo (v10.4),
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
The MTO biobank established in this paper is available to the community upon request, subject to restrictions imposed by the original mouse strain MTAs. All other materials are readily available from indicated standard commercial sources.
